Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva santé animale - inaktiveeritud gripiviiruse a-viirus / siga - immunoloogilised vahendid - sead - aktiivse immuniseerimise sigade alates vanusest 56 päeva aastast, sealhulgas tiinete emiste, vastu sigade gripi põhjustatud alatüüpide h1n1, h3n2 ja h1n2, et vähendada kliinilisi tunnuseid ja viiruse kopsu koormuse pärast nakatumist. algusega immuunsus: 7 päeva jooksul pärast esmase vaccinationduration immuniteedi: 4 kuud sigu vaktsineerida vanuses 56 ja 96 päeva ja 6 kuud sead vaktsineeritud esmakordselt 96 päeva ja rohkem. rasedate emiste aktiivne immuniseerimine pärast esmase immuniseerimise lõpetamist ühe doosiga manustamisel 14 päeva enne poegimist, et arendada kõrge kolstrialse immuunsuse, mis tagab põrsaste kliinilise kaitse vähemalt 33 päeva pärast sündi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - immunoloogilised ravimid, inaktiveeritud viiruse vaktsiinid sigadele, sigade katku viirus - sead - aktiivse immuniseerimise sigade vanuses 8 nädalat aastast vastu pandeemilise h1n1 sigade gripi viirus, et vähendada viiruse kopsu koormus ja viiruse eritumist. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Eesti - eesti - Adama

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Eesti - eesti - Adama

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Eesti - eesti - Ravimiamet

bioveta a.s. - marutaudi elusviirusvaktsiin - suukaudne suspensioon - 1annus 700tk; 1annus 30tk; 1annus 1.8ml 700tk; 1annus 1.8ml 600tk; 1annus 1.8ml 20tk; 1annus 1.8ml 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antineoplastilised ained - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. patsiendid, kellel on egfr-või kristallimise positiivne kasvaja mutatsioonid peaks ka saanud suunatud ravi enne saanud keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Eesti - eesti - Ravimiamet

boehringer ingelheim international gmbh - olodaterool+tiotroopium - inhalatsioonilahus - 2,5mcg+2,5mcg 1mõõtannus 60mõõtannus 3tk; 2,5mcg+2,5mcg 1mõõtannus 60mõõtannus 1tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - piperatsilliin+tasobaktaam - infusioonilahuse pulber - 4000mg+500mg 25tk; 4000mg+500mg 50tk; 4000mg+500mg 12tk

Eesti - eesti - Ravimiamet

boehringer ingelheim international gmbh - olodaterool+tiotroopium - inhalatsioonilahus - 2,5mcg+2,5mcg 1mõõtannus 60mõõtannus 2tk; 2,5mcg+2,5mcg 1mõõtannus 60mõõtannus 3tk; 2,5mcg+2,5mcg 1mõõtannus 60mõõtannus 8tk

Eesti - eesti - Ravimiamet

aurobindo pharma (malta) limited - piperatsilliin+tasobaktaam - infusioonilahuse pulber - 2000mg+250mg 12tk; 2000mg+250mg 1tk; 2000mg+250mg 10tk